Number of COVID-19 treatment vaccine trials worldwide by type June 2022

Number of coronavirus (COVID-19) clinical trials for drugs and vaccines worldwide as of June 3, 2022, by type*

Loading statistic...
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

June 2022

Region

Worldwide

Survey time period

as of June 3, 2022

Supplementary notes

* Definition of listed types:
Treatment: Trials intending to treat (rather than prevent) novel coronavirus (2019-nCoV, COVID-19).
COVID-19 Complication Support: Trials aiming to prevent or treat complications of COVID-19 infection, such as ARDS, Cytokine storm, AKI, Sepsis, etc.
Novel coronavirus (2019-nCoV, COVID-19) pneumonia: Trials that aim to treat or prevent pneumonia due specifically to novel coronavirus (2019-nCoV).
Severe COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms (requiring supplemental oxygen) at screening.
Moderate COVID-19: Trials enrolling subjects with confirmed COVID-19 that have moderate symptoms (respiratory symptoms but supplemental oxygen not needed) at screening.
Mild COVID-19: Trials enrolling subjects with confirmed COVID-19 that have mild upper respiratory symptoms at trial screening.
Novel coronavirus (2019-nCoV, COVID-19) vaccines: Trials with vaccines intended to prevent/treat novel coronavirus (2019-nCoV, COVID-19).
Critical COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms at screening and are in the ICU for critical support. These subjects are likely already on ventilatory support.
Exposure prophylaxis (PEP/PrEP): Trials aiming to prevent COVID-19 infection in subjects at high risk of exposure (ex. Healthcare workers). Includes trials where confirmed exposure has taken place (post-exposure prophylaxis: PEP) as well as trials treating subjects prior to first exposure (pre-exposure prophylaxis: PrEP).
Healthy subjects: Trials enrolling only healthy subjects.
Asymptomatic COVID-19: Trials enrolling subjects with confirmed COVID-19 that are asymptomatic at screening.
Post-COVID Syndrome: Trials aiming to treat Post-COVID Syndrome, including treatment of persistent lung, cardiac or kidney injury after COVID-19 infection.
Unspecified: Trials enrolling patients (not healthy volunteers) but not otherwise specified.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

20

Further Content: You might find this interesting as well

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Learn more about how Statista can support your business.